Advertisement

COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision

Published on: 

SAP Partners | <b>Community Oncology Alliance (COA)</b>

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy, saying that while they are pleased with the direction of covering the therapy, they have concerns with the language included in the memo.

Advertisement

According to COA, CMS should not limit CAR T-cell coverage to hospitals, with many community oncology practices having the experience and capability to administer the therapy. Read the full comment letter.


Advertisement
Advertisement